These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30297283)

  • 1. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.
    Boutin S; Roy J; Maltais R; Alata W; Calon F; Poirier D
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3554-3559. PubMed ID: 30297283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency.
    Boutin S; Maltais R; Roy J; Poirier D
    Eur J Med Chem; 2021 Jan; 209():112909. PubMed ID: 33081987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase.
    He XY; Wegiel J; Yang SY
    Brain Res; 2005 Apr; 1040(1-2):29-35. PubMed ID: 15804423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Bellavance E; Luu-The V; Poirier D
    J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y; Cadot C; Fournier MA; Poirier D
    Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders.
    Yang SY; He XY; Isaacs C; Dobkin C; Miller D; Philipp M
    J Steroid Biochem Mol Biol; 2014 Sep; 143():460-72. PubMed ID: 25007702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
    Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
    Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
    Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Brozic P; Lanisnik Risner T; Gobec S
    Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10.
    Hanzlova M; Slavikova B; Morozovova M; Musilek K; Rotterova A; Zemanová L; Kudova E
    ACS Omega; 2024 Mar; 9(10):12116-12124. PubMed ID: 38496976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.
    Benek O; Vaskova M; Miskerikova M; Schmidt M; Andrys R; Rotterova A; Skarka A; Hatlapatkova J; Karasova JZ; Medvecky M; Hroch L; Vinklarova L; Fisar Z; Hroudova J; Handl J; Capek J; Rousar T; Kobrlova T; Dolezal R; Soukup O; Aitken L; Gunn-Moore F; Musilek K
    Eur J Med Chem; 2023 Oct; 258():115593. PubMed ID: 37390508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase.
    Yang SY; He XY; Schulz H
    Trends Endocrinol Metab; 2005; 16(4):167-75. PubMed ID: 15860413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of Type 10 17β-Hydroxysteroid Dehydrogenase in the Pathogenesis of Infantile Neurodegeneration and Alzheimer's Disease.
    He XY; Frackowiak J; Dobkin C; Brown WT; Yang SY
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
    Poirier D
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically relevant fluorescent assay for identification of 17β-hydroxysteroid dehydrogenase type 10 inhibitors.
    Schmidt M; Vaskova M; Rotterova A; Fiandova P; Miskerikova M; Zemanova L; Benek O; Musilek K
    J Neurochem; 2023 Oct; 167(2):154-167. PubMed ID: 37458164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
    Tremblay MR; Poirier D
    J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.